Pfizer (PFE)
Coverage summary
Aardvark Labs Capital Research has covered Pfizer (PFE) since November 5, 2025. The company is in the Healthcare sector. This page lists 5 reports: 5 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published November 5, 2026. That report moved the rating from Outperform to Hold. The rating has changed twice since coverage began.
Translations: 4 in Chinese.
Rating history
All PFE reports
Recap: Q3 2026
Pfizer Beat and Raised Again, but at $30 the Market Has Already Paid for the Turnaround
Recap: Q2 2026
Pfizer Cut COVID by a Billion and Raised the Guide Anyway: The Offset Engine Finally Outran the Decline
Recap: Q1 2026
The Cliff Just Got Shorter: Pfizer's Vyndamax Settlement Changes the Math and Earns an Upgrade
Recap: Q4 2025
Pfizer Beat the Quarter and Sold the Guide: The Patent Cliff Is Now the Whole Story
Recap: Q3 2025
Pfizer Beat by a Third and Raised by an Eighth: What Management Kept Tells You What the Quarter Was Worth